- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: HSDB 7455 | IDEC-C2B8 | MabThera® | Rituxan®
rituximab is an approved drug (FDA (1997), EMA (1998))
Compound class: Antibody
Comment: Rituximab is a type I anti-CD20 monoclonal, designed to target surface CD20 on B-lymphocytes. It is a cancer and autoimmune disease drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
View more information in the IUPHAR Pharmacology Education Project: rituximab
1. Ambrus Jr. JL. (2017)
Sjogren's syndrome: New paradigms and areas for future research.
Clin. Immunol., 182: 1-3. [PMID:28673862]
2. Anderson DR, Nabil H, Leonard JE, Newman RA, Reff ME, Rastetter WH. (1998)
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma.
Patent number: US5843439. Assignee: Anderson DR, Nabil H, Leonard JE, Newman RA, Reff ME, Rastetter WH. Priority date: 13/11/1992. Publication date: 01/12/1998.
3. Anderson DR, Rastetter WH, Hanna N, Leonard JE, Newman RA, Reff ME. (1994)
Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma.
Patent number: WO1994011026. Assignee: Idec Pharma Corp. Priority date: 26/02/2015. Publication date: 26/05/1994.
4. Fehr T, Stussi G. (2012)
ABO-incompatible kidney transplantation.
Curr Opin Organ Transplant, 17 (4): 376-85. [PMID:22790072]
5. Macklin PS, Morris PJ, Knight SR. (2015)
A systematic review of the use of rituximab as induction therapy in renal transplantation.
Transplant Rev (Orlando), 29 (2): 103-8. [PMID:25555541]
6. Stein R, Qu Z, Chen S, Rosario A, Shi V, Hayes M, Horak ID, Hansen HJ, Goldenberg DM. (2004)
Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Clin. Cancer Res., 10 (8): 2868-78. [PMID:15102696]
7. Verstappen GM, van Nimwegen JF, Vissink A, Kroese FGM, Bootsma H. (2017)
The value of rituximab treatment in primary Sjögren's syndrome.
Clin. Immunol., 182: 62-71. [PMID:28478105]